SCHEMBL6861763

SCHEMBL6861763

O=C(NC1CCC(Nc2ccnc3cc(Cl)ccc23)CC1)c1cccc(F)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.58
KMT5B Q4FZB7 1/20 0.57
KMT5C Q86Y97 1/20 0.57
NSD2 O96028 1/20 0.54
GRM5 P41594 4/20 0.53
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
KMT2A Q03164 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
ALDH1A1 P00352 1/20 0.50
ADRA2A P08913 2/20 0.49
MCHR1 Q99705 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
CCNE1 P24864 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861766 1.00 AR (0.58) ARKMT5BKMT5CNSD2GRM5
SCHEMBL6870396 0.91 KMT5B (0.61) ARKMT5BKMT5CNSD2CYP2D6
SCHEMBL6870394 0.91 KMT5B (0.61) ARKMT5BKMT5CNSD2CYP2D6
SCHEMBL6869974 0.89 KMT5B (0.58) ARKMT5BKMT5CNSD2CYP2D6
SCHEMBL6865536 0.89 KMT5B (0.58) ARKMT5BKMT5CNSD2GRM5
SCHEMBL6865533 0.89 KMT5B (0.58) ARKMT5BKMT5CNSD2GRM5
SCHEMBL6870599 0.89 KMT5B (0.61) ARKMT5BKMT5CNSD2GRM5
SCHEMBL6870596 0.89 KMT5B (0.61) ARKMT5BKMT5CNSD2GRM5
SCHEMBL6869339 0.88 KMT5B (0.57) ARKMT5BKMT5CNSD2GRM5
SCHEMBL6870166 0.88 KMT5B (0.57) ARKMT5BKMT5CNSD2GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US claimed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US claimed
US-6818772-B2 DIETETICS, SLEEP DISORDERS, EATING DISORDERS, SEXUAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS ABBOTT LABORATORIES 2004-11-16 US disclosed
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor ABBVIE INC. 2003-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229119-A1 Antagonists of melanin concentrating hormone effects on the melanin concetrating hormone receptor MCHR1, MCHR2, MC1R AR 467/4885KMT5B 1214/4885KMT5C 1285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.